Article Text

SAT0429 The OA TRIAL Bank: Meta-Analysis of Individual Patient Data Show That Patients with Severe Pain or with Inflammatory Signs Detected by Ultrasound Especially Benefit from Intra-Articular Glucocorticoids for Knee or Hip Oa
  1. M. Van Middelkoop1,
  2. N. Arden2,
  3. I. Atchia3,
  4. F. Birrell4,
  5. J. Chao5,
  6. R. Lambert6,
  7. P. Ravaud7,
  8. J.W. Bijlsma8,
  9. M. Doherty9,
  10. K. Dziedzic10,
  11. S. Lohmander11,
  12. T. McAlindon12,
  13. W. Zhang9,
  14. S. Bierma-Zeinstra13
  15. on behalf of EULAR OA Trial Data Bank Study Group
  1. 1General Practice, Erasmus Mc Medical University, Rotterdam, Netherlands
  2. 2University of Oxford and Southampton, Oxford
  3. 3North Tyneside General Hospital
  4. 4Newcastle University, Newcastle, United Kingdom
  5. 5Hospital of San Diego, San Diego, United States
  6. 6University of Alberta, Edmonton, Canada
  7. 7l'Université Pierre et Marie Curie, Paris, France
  8. 8UMC Utrecht, Utrecht, Netherlands
  9. 9University of Nottingham, Nottingham
  10. 10Primary Care Sciences Keele University, Keele, United Kingdom
  11. 11Lund University, Lund, Sweden
  12. 12Tufts University, Boston, United States
  13. 13Erasmus MC Medical University, Rotterdam, Netherlands


Background Based on small to moderate effect sizes for the wide range of symptomatic treatments in osteoarthritis (OA) and on the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on clinical predictors of response to treatment.

Objectives To evaluate the efficacy of intra-articular (IA) glucocorticoids for knee and hip OA for subgroups of patients with severe pain, and inflammation on short term follow-up using IPD from existing trials.

Methods Randomized trials evaluating one or more IA glucocorticoid preparation in patients with knee or hip OA, published from 1995 up to June 2012 were selected from the existing literature. The presented preliminary analyses include the comparison between IA glucocorticoids and placebo, since data included in this comparison are complete. Individual data obtained from original trials included patient characteristics, disease characteristics and outcomes measured. All analyses were performed following our published protocol.(1) The primary outcome was pain severity at short-term follow-up (up to 4 weeks). The subgroup factors assessed included severe pain and signs of inflammation. A multilevel regression analysis was applied to calculate the interaction effects. Analyses were adjusted for baseline pain severity, age, gender and BMI.

Results Seven published randomized clinical trials including 309 patients were included.(additional data of 360 patients affirmed). Of these, four studies (n=225) compared glucocorticoids with placebo.

A significant positive interaction was found between severe pain at baseline and treatment effect (interaction coefficient 13.6, 95%CI 1.4-25.8). A non-significant overall interaction estimate was found for inflammatory signs 12.5 (95%CI -7.22-32.3). However, a strongly positive interaction estimate (45.3, 95%CI 24.4-66.1) was found for inflammation and treatment effect when analyzed in the studies where inflammation was measured by ultrasound.

Conclusions Patients with severe pain at baseline do benefit significantly more from IA glucocorticoid injections than those with less severe pain. However inflammation defined by ultrasound provided an even more significant measure of a positive treatment response of IA glucocorticoids in patients with knee or hip OA. The differences in treatment response at short-term follow-up between IA glucocorticoid treatment and IA placebo were much larger when inflammatory signs, measured by ultrasound, were present compared to absence of inflammatory signs.


  1. van Middelkoop M, Dziedzic KS, Doherty M, et al. Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid injections in patients with knee or hip osteoarthritis: an OA Trial Bank protocol for a systematic review. Syst Rev. 2013;2:54.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.2250

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.